Product Name: C-rel Antibody
Species Reactivity: Human, Mouse
Tested Applications: WB
Applications: For WB starting dilution is: 1:1000
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 69 kDa
Immunogen: This C-rel (NFkB) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 586-619 amino acids from the C-terminal region of human C-rel (NFkB).
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 1146-98-1
Product: Bromindione
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Proto-oncogene c-Rel, REL
Accession NO.: Q04864
Protein Ino: 548720
Official Symbol: REL
Geneid: 5966
Background: Nuclear factor (NF)-kappa B is a sequence specific transcriptional activator that binds to the intronic enhancer of kappa light chain gene in B lymphocytes. NF-kB regulates the expression of a wide variety of genes that involved in apoptosis, viral life cycle, tumorigenesis, autoimmune diseases and inflammation. NF-kB is a heterodimer of members of the rel family of proteins such as p50, p65, and c-rel. In most cells, inhibitory IkB proteins sequester NF-kB/Rel in the cytoplasm. Cellular stimulation precipitates degradation of IkB and modification of NF-kB/Rel proteins, permitting translocation of NF-kB/Rel (c-Rel and RelA) to the nucleus for action on target genes. The important role of c-Rel in B-cell development, growth, and survival has been intensively studied, as well as its function in differentiation and lymphopoiesis (particularly lymphoid cancer).
PubMed ID:http://aac.asm.org/content/42/7/1751.abstract
